AWA
ACAD icon

Aaron Wealth Advisors’s Acadia Pharmaceuticals ACAD Stock Holding History

Aaron Wealth Advisors’s Portfolio ACAD Stock Details ACAD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q2 		– Sell
-388
Closed -$9.4K – 196
2022
Q1 		$9.4K Buy
+388
New +$9.39K ﹤0.01% 807

Other funds holding ACAD

BBA
Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
EC
EcoR1 Capital San Francisco, California $2.06B AUM 215.32% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return
RI
RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Aaron Wealth Advisors's ACAD Position: Q2 2022 in Review

Aaron Wealth Advisors sold out of Acadia Pharmaceuticals (ACAD) in Q2 2022, closing a stake of 388 shares — an estimated $9.4K sold.

Aaron Wealth Advisors first reported a position in ACAD in Q1 2022 and held it in 1 quarter. The position peaked at $9.4K in Q1 2022. 246 funds tracked by Wall St. Rank hold ACAD as of Q2 2022.

  • Aaron Wealth Advisors reported no remaining Acadia Pharmaceuticals position as of Q2 2022 after selling out during the quarter.
  • Aaron Wealth Advisors sold 388 Acadia Pharmaceuticals shares in Q2 2022, an estimated $9.4K.
  • Aaron Wealth Advisors first reported a position in Acadia Pharmaceuticals in Q1 2022 and held it in 1 quarter.
  • Aaron Wealth Advisors's Acadia Pharmaceuticals position peaked at $9.4K in Q1 2022.
  • 246 funds tracked by Wall St. Rank held Acadia Pharmaceuticals as of Q2 2022.

Based on Aaron Wealth Advisors's 13F filing for Q2 2022, filed 22 Jul 2022.